Neurotechnology
Brain-Computer Interfaces
An emerging medical-device category using implanted or minimally invasive electrode arrays to translate neural signals into digital commands, initially targeting paralysis and speech-loss patients. Human trials accelerated sharply in 2026, with Neuralink reaching its 26th trial participant, Synchron raising $200 million for a 2026 FDA pivotal trial, and Precision Neuroscience clearing FDA 510(k) review for its Layer 7 Cortical Interface, as industry estimates put the near-term BCI market at $8-12 billion.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source · 74% avg. source confidence
- MIT Technology Review — Brain-computer interface trials are taking off74% source confidence
Dependency Map
What Brain-Computer Interfaces depends on below, and who depends on Brain-Computer Interfaces above — click any node to make it the new center, 5 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Brain-Computer Interfaces's Timeline
A sourced, dated history of Brain-Computer Interfaces's key moments — founding to present.
Jun 2026 · BCI human trials accelerate industry-wide
Neuralink, Synchron and Precision Neuroscience all advanced human clinical programs in the first half of 2026, with MIT Technology Review describing brain-computer interface trials as 'taking off' amid a widening field of competitors.
Source